Merck’s Mevacor Returns For OTC Switch Consideration
This article was originally published in The Tan Sheet
Executive Summary
Merck is in discussions with potential marketing partners for its third Rx-to-OTC switch attempt for the statin Mevacor, as the date approaches for an FDA advisory committee review of the drug
You may also be interested in...
FDA Advisors Say Greater Insight Needed On Self-Selection Of OTC Statins
More information from "real world" experiences on how consumers make OTC selections may be needed to pull off a successful Rx-to-OTC switch of a statin
FDA Advisors Say Greater Insight Needed On Self-Selection Of OTC Statins
More information from "real world" experiences on how consumers make OTC selections may be needed to pull off a successful Rx-to-OTC switch of a statin
FDA Advisors Say Greater Insight Needed On Self-Selection Of OTC Statins
More information from "real world" experiences on how consumers make OTC selections may be needed to pull off a successful Rx-to-OTC switch of a statin